transplant platelet count
The evaluation of allogeneic bone marrow transplant (BMT) recipients at 100 days post transplant has become a common standard of practice. Studies have shown that a variety of variables at day þ 100 may predict for the development of chronic graft-versus-host disease (GVHD) and other toxicities. [1] [2] [3] Thrombocytopenia has been described as a marker for high-or low-risk chronic GVHD. Thrombocytopenia post transplant has recently been described as a variable associated with decreased survival. [4] [5] [6] [7] Given the ease of determining the platelet count 100 days post transplant, this report describes a straightforward retrospective review of 107 consecutive allogeneic BMT recipients at a single institution receiving an ablative allogeneic transplant from 7/96 to 12/00 who survived at least 100 days, examining the day þ 100 platelet count with respect to survival.
Patients and methods
A total of 107 adult patients with hematological malignancies underwent allogeneic BMT at the Cleveland Clinic Foundation from 7/96 to 12/00 and survived at least 100 days. Eligibility for allogeneic BMT included a cardiac ejection fraction of 450%, normal serum bilirubin, either a normal creatinine or creatinine clearance of 460 ml/min, and adequate pulmonary function testing. All patients were treated on protocols reviewed and approved by the Cleveland Clinic Foundation Institutional Review Board, with informed consent obtained from all patients. Patient characteristics are shown in Table 1 . 'Good risk' disease was defined as those in remission or chronic myelogenous leukemia in the chronic phase, or aplastic anemia; 'bad risk' was defined as those with active disease at the time of transplant.
Ablative BMT preparative regimen
Of 107 patients, 97 received busulfan-based preparative regimens (91%); the majority received busulfan/cyclophosphamide/etoposide (67%) and 22% received busulfan and cyclophosphamide. Other preparative regimens were TBIcyclophosphamide (n ¼ 7); and cyclophosphamide-ATG (n ¼ 3). Patients received allogeneic bone marrow; no patients received allogeneic PBPCs. All patients had serologic matched sibling or matched (at least 5/6 loci) unrelated donors. Cyclosporine and low-dose methotrexaten were given routinely for GVHD prophylaxis. Patients receiving an unrelated allogeneic BMT also had selective CD8 T-cell depletion employed.
CD8 T-cell depletion
T-cell depletion (CD8 þ ) of the bone marrow was performed immunomagnetically using a CD8 antibody coupled to a superparamagnetic bead (Dynal Biotech). After preparing a mononuclear cell concentrate from the bone marrow and determining a lymphocyte count, the mononuclear cell product was incubated in a tissue culture flask with gentle rotation at 41C for 30 min in phosphatebuffered saline with 1.25% human albumin at a cell : bead ratio of at least 1 : 4. After incubation, the product was passed over a magnet (MaxSep, Baxter, Inc.) to remove CD8 þ cells bound to the beads. Following CD8 depletion, the product was centrifuged and the supernatant pressed off. Aliquots of the bone marrow prior to and following processing were taken for cell count, flow cytometry (CD3, CD4, CD8, CD34), viability, CFU assay, and sterility testing.
Supportive care
Patients were hospitalized for the delivery of high-dose chemotherapy and discharged after adequate hematological recovery occurred. Platelet or RBC transfusions were routinely administered when the platelet count was o15 Â 10 9 /l or hemoglobin was o8.5 g/dl, respectively. All blood products were irradiated prior to infusion. Broad-spectrum antibiotics were administered for febrile neutropenic episodes. G-CSF was used for neutropenia. No growth factors were given for thrombocytopenia. Patients who were serologically positive for CMV, or who had donors who were serologically positive for CMV, received ganciclovir prophylaxis after engraftment until day þ 100, and acyclovir thereafter.
Patient follow-up
All patients were followed at the Cleveland Clinic Foundation after transplant. All patients obtained weekly complete blood count analysis for the first 60-80 days post transplant, and as clinically indicated thereafter. All patients received a routine CBC 100 days after allogeneic BMT; the platelet count will be referred to as 'day þ 100 platelet count.'
Statistical analysis
Descriptive statistics are summarized for categorical variables as frequencies and percentages, and for continuous variables as the median and range. Survival is defined as the time from BMT to death or final follow-up; relapse-free survival is defined as the time from transplantation to relapse, death, or final follow-up.
Survival tree analysis (recursive partitioning analysis for censored data) with a log-rank splitting method was used to identify cutpoints in day þ 100 platelet counts that separate patients into distinct groups on the basis of their survival. This analysis was performed using STREE software for censored survival data developed by Zhang and Singer. 8 For the sake of clinical utility, the cutpoints identified were rounded to whole numbers. Survival estimates were then estimated for the resulting groups using the method of Kaplan and Meier, and compared among groups using the log-rank test.
Cox proportional hazards analysis was used to identify univariable and multivariable risk factors for mortality. A stepwise selection procedure was used that allowed variables to enter the model if Po0.10 but required Po0.05 for variables to remain in the final model. The following variables were considered as potential risk factors: time from diagnosis to transplant, age at transplant, gender, prior radiation therapy, number of prior chemotherapy regimens, donor relationship, risk category, development of any aGVHD, development of grade II-IV aGVHD, donor to recipient gender (same or different), and day þ 100 platelet count. The estimated survival was generated from the resulting multivariable Cox model for two extreme patient profiles: patients with all of the risk factors and patients with none of the risk factors.
All analyses were conducted using SAS s software. All statistical tests were two-sided; Po0.05 was used to indicate statistical significance.
Results
A 4-year survival and a relapse-free survival for the entire group are 45 and 39%, respectively. The mean follow-up for surviving patients is 48 months. Survival tree analysis identified three groups based on day þ 100 platelet count: o30, 30-50, and 450 Â 10 9 /l. A 4-year survival among these groups is 19, 41, and 72%, respectively (Po0.001; log-rank test).
Risk factors for mortality
Univariable analysis identified lower day þ 100 platelet count and bad risk disease as significant risk factors for mortality, and a matched unrelated donor as a 
Prognostic importance of platelet count B Bolwell et al marginally nonsignificant risk factor (Table 2) . Multivariable analysis revealed that bad risk disease and lower day þ 100 platelet count were significant independent risk factors for mortality (Table 2) . Survival by platelet count is shown graphically in Figure 1 . Figure 2 shows the predicted survival for patients with the best and worst combination of risk category and platelet count. We then investigated whether other clinical parameters affected the day þ 100 platelet count. The incidence of Tcell depletion was similar in the o30, 30-50, and 450 groups (29, 29, and 19%, respectively, P ¼ 0.50, w 2 test). The total dose of cells infused, both in non-T-cell depleted and in T-cell depleted patients, was similar for the three treatment groups. Ganciclovir is known to cause marrow suppression. Of the 73 patients on ganciclovir, 59 were on a prophylactic regimen and only 14 for treating a positive CMV blood culture. The incidence of ganciclovir usage, defined as at least 30 days of ganciclovir from day þ 40 to day þ 100, was similar in the three groups (65, 67, 73%, respectively, P ¼ 0.71, w 2 test). In total, 78% of all patients had some degree of acute GVHD. We empirically defined /l required a prednisone dose of at least 30 mg, compared to 58% in the 30-50 group, and 31% in the 450 group (Po0.001; w 2 test). Although prednisone use differed among groups, it was not a risk factor for mortality. Of note, there was no statistically significant difference in the WBC on day þ 100 by the platelet group. No other pre transplant variable correlated with the platelet group.
Cause of treatment failure
For analysis of cause of treatment failure, the groups with a platelet count o30 and 30-50 were combined. In total, 58 patients have died: 47 with a day þ 100 platelet count of p50 and 11 with a platelet count of 450. The causes of death were different depending on the day þ 100 platelet count: in the group with a platelet count p50, 32% of deaths were due to disease relapse and 68% due to transplant-related complications; in contrast, 82% of deaths in the group with a platelet count 450 were due to disease relapse. Only one patient in the platelet count 450 group died of chronic GVHD, as compared to 16 patients, or 34%, in the group with a platelet count o50. The most common cause of treatment-related failure in the group with a platelet count o50 was GVHD, which was the cause of death in 40% of patients. Infectious complications were the cause of death in 15% of this cohort, and of these, the majority was due to fungal infections.
Discussion
Many pre BMT variables are reportedly predictive of transplant outcome. The most extensively studied variable is the age of the patient at the time of transplant. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The predictive value of age, however, is not precisely defined; some studies show that age is an independent risk factor for mortality, whereas others do not. Most studies reveal that the older the adult, the higher the risk of chronic GVHD and higher the risk of transplant-related mortality. However, no study has shown an age cutoff above which the risk of transplant is prohibitive. The additional pre transplant variables that have been reported to influence transplant outcome include cardiac and pulmonary evaluation; 20,21 the source of the donor, the degree of HLA matching of the donor, and sex mismatching of the donor-recipient pair. [22] [23] [24] [25] Fewer post transplant variables have been reported to influence transplant outcome. An original report indicated that 'screening studies' performed day þ 100 after allogeneic BMT were clinically useful. The prime motivation was to determine if a patient with clinically absent GVHD had a positive pathologic biopsy for GVHD, which would lead to appropriate therapy. A subsequent series from the same institution, however, did not confirm the value of screening studies. 7 Several studies have shown that thrombocytopenia is an adverse prognostic variable after allogeneic BMT. [4] [5] [6] Some studies have used a platelet count of 100 Â 10 9 /l, and other studies used different criteria to define thrombocytopenia. The first study discussing thrombocytopenia after allogeneic BMT was a pediatric study, in which patients with a platelet count o100 Â 10 9 /l for 100 days post transplant had decreased survival and an increased incidence of severe acute GVHD and chronic GVHD. 4 More recently, Przepiorka et al 6 used a platelet count of 100 Â 10 9 /l as a criteria to define chronic GVHD as severe; those with a platelet count o100 Â 10 9 /l had increased overall mortality and increased treatment failure 18 months post transplant.
Our study demonstrates that the primary reason why thrombocytopenic patients have a higher mortality risk is not due to disease relapse, but rather, a striking incidence of treatment related failure. The most common cause of treatment failure was due to chronic GVHD. We did note that more patients in the platelet count o30 Â 10 9 /l group required higher doses of prednisone to treat GVHD than did the other cohorts. Infectious complications may also be associated with thrombocytopenia. It is difficult to decipher the precise etiology of thrombocytopenia in the post transplant period; clearly it is associated with other significant complications.
The challenge is how to treat patients who are thrombocytopenic at day þ 100 after allogeneic BMT. In our study, seven patients died of infection, a far lower incidence than did those dying of GVHD. One could therefore argue that patients with marked thrombocytopenia at day þ 100, in the absence of active clinical infections, might be treated with more intensive immunosuppressive therapy for ongoing GVHD, or, at the very least, be candidates for alternative GVHD clinical trials. The issue of severe chronic GVHD and thrombocytopenia after allogeneic BMT is vexing. While chronic GVHD may be important to obtain an ongoing graft-versus-tumor (GVT) effect, the benefit is frequently negated by the complications associated with severe chronic GVHD.
In contrast, patients with a platelet count 450 at day þ 100 have a favorable prognosis, with the vast majority remaining in complete remission with extended follow-up. Indeed, the most frequent cause of treatment failure in this group is disease relapse. For those patients at high risk of disease relapse with a platelet count 450 Â 10 9 /l at day þ 100, one could suggest rapid reduction of immunosuppression to maintain a GVT effect.
In conclusion, the day þ 100 platelet count is an easily measured variable that powerfully predicts survival following allogeneic BMT. Clinical research targeting thrombocytopenic patients is needed to improve the poor outcome for patients with profound thrombocytopenia at day þ 100.
